Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RANI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRani Therapeutics holds routine annual meeting, elects seven directors and ratifies auditor
Filed May 29, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
low
Seven directors elected to serve until 2027 annual meeting, including CEO Talat Imran and founder Mir Imran, with votes ranging from 52.5M to 57.4M in favor.
Item 5.07 verify on EDGAR → -
low
Stockholders ratified CBIZ CPAs P.C. as independent auditor for fiscal 2026 with 77M votes for versus 333K against, confirming audit committee's selection.
Item 5.07 verify on EDGAR →
Summary
Rani Therapeutics held its annual stockholder meeting on May 28, 2026, completing standard corporate governance matters. The company's stockholders re-elected all seven director nominees to serve one-year terms through the 2027 annual meeting, maintaining board continuity with leadership including CEO Talat Imran and founder Mir Imran. The board also includes independent directors with expertise in medicine, finance, and life sciences.
In a separate vote, stockholders overwhelmingly ratified the audit committee's appointment of CBIZ CPAs P.C. as the company's external auditor for fiscal 2026. This is a routine annual compliance matter with no operational or financial implications. Investors should watch for the company's upcoming quarterly earnings report and any updates on its oral drug delivery technology pipeline, as those will provide more meaningful insights into business performance than these procedural governance votes.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 29, 2026 · How we verify